IPHA लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 01:30):

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally...

Stats
आज की मात्रा	6 642.00
औसत मात्रा	9 586.00
बाजार मूल्य	205.34M
EPS	$0 ( 2024-03-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-25.40
ATR14	$0.0620 (2.57%)

Innate Pharma S.A. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
ANPC	0.951
EWCZ	0.947
BWEN	0.935
CDZI	0.931
GBLI	0.93
EEFT	0.924
FSV	0.921
AMSC	0.921
CCOI	0.918
FGEN	0.917

10 सबसे अधिक नकारात्मक सहसंबंध
SGLB	-0.943
LARK	-0.917
OP	-0.915
HMNF	-0.908
RIVN	-0.908
SMMF	-0.897
MGTA	-0.892
UTME	-0.892
DBDR	-0.892
PIII	-0.887

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Innate Pharma S.A. वित्तीय

Annual	2023
राजस्व:	$51.90M
सकल लाभ:	$-4.12M (-7.94 %)
EPS:	$-0.0941

FY	2023
राजस्व:	$51.90M
सकल लाभ:	$-4.12M (-7.94 %)
EPS:	$-0.0941

FY	2022
राजस्व:	$49.64M
सकल लाभ:	$-2.02M (-4.08 %)
EPS:	$-1.240

FY	2021
राजस्व:	$12.11M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-1.681

Financial Reports:

No articles found.

Innate Pharma S.A.

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.